Comparative Risk of Cancer Recurrence During Treatment With Biologics: A Meta-Analysis
Daniel Isufi, Christopher Willy Schwarz, Mikkel Bak Jensen, Jakob Seidelin, Lone Skov, Nikolai Loft · 2026
Read Comparative Risk of Cancer Recurrence During Treatment With Biologics: A Meta-Analysis by Daniel Isufi, Christopher Willy Schwarz, Mikkel Bak Jensen, Jakob Seidelin, Lone Skov, Nikolai Loft (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13625878.txt.
Description
Daniel Isufi and co-authors weigh cancer risk in a 2026 meta-analysis on biologic drugs. People with immune-driven inflammatory diseases who have already had cancer pose a dilemma: biologic labels urge caution, and trials excluded them, yet stopping effective treatment carries its own costs.
Earlier work compared biologics with older systemic drugs, a design open to bias. This review instead compares biologic against biologic. Four studies covering several hundred patients were pooled with random-effects methods, contrasting tumor necrosis factor inhibitors with other biologic classes. The analysis asks whether any biologic family stands out as safer for cancer survivors.
Catalog record
| CREATOR | Daniel Isufi, Christopher Willy Schwarz, Mikkel Bak Jensen, Jakob Seidelin, Lone Skov, Nikolai Loft |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 8 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |